Kolkata News Today

Dyskinesia Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Dyskinesia Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 30
14:30 2022
Dyskinesia Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Dyskinesia pipeline constitutes 40+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Dyskinesia Overview

Dyskinesia is a movement disorder that often appears as uncontrolled shakes, tics, or tremors. Often, the condition occur in people with Parkinson’s disease due to the overstimulation of their dopamine receptors from medications that increase this neurotransmitter in the brain. One common example of a Parkinson’s medication that can have this effect is levodopa. Another type of dyskinesia is tardive dyskinesia, which occurs when a person takes certain dopamine receptor-blocking medications.

 

Dyskinesia Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market. 

 

The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Dyskinesia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years. Dyskinesia Key players such as – Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment 
  • Dyskinesia Emerging therapies such as – CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years. 
  • In April 2019, Bukwang Pharmaceutical initiated a trial titled, “A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients with Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components”. Subjects with a diagnosis of PD and dyskinesia as in PD will complete a Screening Visit to assess eligibility to participate in the study
  • In July 2019, Contera Pharma initiated a trial titled, “A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010”. The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials
  • In February 2020, Bukwang received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase II clinical study of JM-010. JM-010, originating from a Danish bio venture company Contera Pharma, is currently under development for treating dyskinesia which emerges in up to90% of Parkinson’s disease patients following long term treatment of levodopa 

 

Dyskinesia Pipeline Therapeutics Assessment

  • Dyskinesia Assessment by Product Type
  • Dyskinesia By Stage and Product Type
  • Dyskinesia Assessment by Route of Administration
  • Dyskinesia By Stage and Route of Administration
  • Dyskinesia Assessment by Molecule Type
  • Dyskinesia by Stage and Molecule Type 

 

DelveInsight’s Dyskinesia Report covers around 45+ products under different phases of clinical development like:

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:

  • CP 011: Contera Pharma
  • PCT-3012: PolyCore Therapeutics
  • Mesocarb: Melior Pharmaceuticals
  • ML 007: MapLight Therapeutics
  • LY 03015: Luye Pharma Group
  • JM-010 : Contera Pharma
  • NLX 112: Neurolixis
  • CPL 500036: Celon Pharma 

 

Dyskinesia Pipeline Analysis:

 

The Dyskinesia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Dyskinesia treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
  • Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies

 

Dyskinesia Pipeline Market Drivers

  • Increase in prevalence of Dyskinesia
  • Increase in the demand for disease specific novel treatment

 

Dyskinesia Pipeline Market Barriers

  • Lack of understanding of the pharmacology of Dyskinesia
  • Side-effects associated with drugs

 

Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Assessment

 

Scope of Dyskinesia Pipeline Drug Insight    

  • Coverage: Global
  • Key Dyskinesia Companies: Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
  • Key Dyskinesia Therapies: CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
  • Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
  • Dyskinesia Market Dynamics:  Dyskinesia market drivers and Dyskinesia market barriers 

 

Request for Sample PDF Report for Dyskinesia Pipeline Assessment and clinical trials

 

Table of Contents

1

Dyskinesia Report Introduction

2

Dyskinesia Executive Summary

3

Dyskinesia Overview

4

Dyskinesia- Analytical Perspective In-depth Commercial Assessment

5

Dyskinesia Pipeline Therapeutics

6

Dyskinesia Late Stage Products (Phase II/III)

7

Dyskinesia Mid Stage Products (Phase II)

8

Dyskinesia Early Stage Products (Phase I)

9

Dyskinesia Preclinical Stage Products

10

Dyskinesia Therapeutics Assessment

11

Dyskinesia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dyskinesia Key Companies

14

Dyskinesia Key Products

15

Dyskinesia Unmet Needs

16 

Dyskinesia Market Drivers and Barriers

17

Dyskinesia Future Perspectives and Conclusion

18

Dyskinesia Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Dyskinesia drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories